FDA Warns Cornerstone Over Zyflo Marketing

Law360, New York (July 6, 2010, 6:07 PM EDT) -- The U.S. Food and Drug Administration has taken Cornerstone Therapeutics Inc. to task over certain advertising materials for Zyflo CR, saying they omit important risk information associated with the asthma treatment.

The agency's Division of Drug Marketing, Advertising and Communications directed the drugmaker to immediately stop using the inaccurate promotional materials, which include a website and visual aid, and to disseminate a corrective message to anyone who received the misleading product information, according to a warning letter made public Tuesday.

According to the FDA, Cornerstone's website...
To view the full article, register now.